Researchers conducted a study to assess the effectiveness of epigenetic clocks, including PhenoAge, in predicting age-related disease and death. The findings suggest that current epigenetic age acceleration measures do not significantly improve upon traditional correlations with age-related health outcomes, such as socioeconomic status. This indicates a need for further development and refinement of aging clocks before they can be truly impactful. Despite advancements in measurement techniques, DNAm-based age acceleration remains a strong predictor of health outcomes and mortality in older populations. Factors like demographics, SES, and health behaviors still play crucial roles in determining later life outcomes.
The study, utilizing data from the Health and Retirement Study, demonstrates that age acceleration calculated using newer epigenetic clocks is a significant predictor of various health outcomes and mortality. The introduction of PC-based measures did not alter the relationship between age acceleration and health outcomes, emphasizing the importance of continued research and refinement in this area. While DNAm-based age acceleration is a valuable predictive tool, other factors remain equally important in assessing later life health outcomes.
